89 results about "Mood disorders" patented technology

The invention provides a mood disorder assessment system based on multi-level feature fusion, and the system comprises a data collection unit which is used for collecting electroencephalogram signals of a plurality of brain regions of a to-be-assessed patient; the electroencephalogram feature extraction unit is used for extracting electroencephalogram features corresponding to the electroencephalogram signals of the brain regions; the multi-level feature extraction unit is constructed on the basis of the symptom features of the multiple testees and the corresponding electroencephalogram features, and is used for performing multi-level electroencephalogram feature latent variable extraction on the electroencephalogram features of the brain regions of the patient to be evaluated to obtain multi-level electroencephalogram feature latent variables; and the feature fusion and classification unit is used for carrying out classification prediction based on the electroencephalogram feature latent variables to obtain a mood disorder assessment result of the patient to be assessed. The method solves the problem that a mood disorder assessment system in the prior art adopts a single feature extraction and learning strategy and has no constraint of symptom information, so that the recognition capability of a model for mood disorders of different functional abnormality types is limited.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for improving cognition, emotion, memory and depression states and a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following components in parts by mass: radix scutellariae, rhizoma coptidis, radix puerariae, rhizoma anemarrhenae, bitter gourd, rhizoma zingiberis, stiff silkworm, American ginseng and radix notoginseng. Wherein the radix scutellariae and the rhizoma coptidis are monarch drugs and mainly attack the core pathogenesis; the radix puerariae, the rhizoma anemarrhenae and the pseudo-ginseng serve as ministerial drugs, assist monarch drugs and treat secondary pathogenesis; bitter gourd, rhizoma zingiberis, stiff silkworm and American ginseng are used as adjuvant drugs to regulate drug properties and treat and treat both symptoms and root causes; and radix puerariae and pseudo-ginseng are used as conductant drugs for guiding channels or harmonizing the drugs. The traditional Chinese medicine composition disclosed by the invention can be used for preventing and treating cognitive disorder, mood disorder and depressive state caused by metabolic disorder. The traditional Chinese medicine composition is small in side effect, high in individuation and suitable for being taken for a long time, and has an obvious treatment effect.

Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I); and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

Aspects of disclosure relate to a composition and methodology for treating menopause symptoms utilizing a cannabinoid-based nanoplatform composition. The composition includes phytocannabinoids like CBD, CBG, and CBN, alongside isoflavones and polyphenols, all integrated into nanoplatform designed for enhanced bioavailability and controlled release. The formulation is designed to alleviate key menopause-related issues, including vasomotor symptoms (VMS), genitourinary syndrome of menopause (GSM), bone loss, mood disturbances, and sleep disorders, while addressing cardiovascular disease (CVD) risks. The composition combines cannabinoids, such as CBD, with isoflavones and polyphenols, and is incorporated into nanoplatforms for enhanced delivery and efficacy. Additionally, the disclosure includes a kit comprising oral capsules, intravaginal ovules, and instructions for use. The capsules contain a blend of cannabinoids, flavonoids, and polyphenols, while the ovules are composed of CBD and cocoa butter. The kit provides a comprehensive solution for managing menopause symptoms and mitigating cardiovascular risks.

This invention relates to the field of pharmaceutical technology, and discovers that the natural products boldinine and norboldinine can be used as NTSR1 (Neurotensin receptor-1, NTSR1) receptor antagonists and their applications. The compounds are boldinine and norboldinine ((+)-Laurolitsine), which have NTSR1 receptor antagonistic activity and are NTSR1 receptor antagonists that can prevent and treat alcohol poisoning, addiction, schizophrenia, autism spectrum disorder, and mood disorders. Accordingly, this invention can provide novel NTSR1 receptor antagonist prospective compounds with clear targets for the above-mentioned related diseases.

The invention relates to the field of medicines, and discloses a novel human PYY analogue, and compared with a PYY3-36 natural sequence, the novel human PYY analogue has a remarkable effect on improving metabolic diseases such as obesity, diabetes and fatty liver and emotional diseases such as anxiety disorder and depression.

This invention discloses a method for screening or assessing the risk of GLP-1 receptor agonist-related mood disorders. It reveals for the first time that TTR is a key molecular switch for the bidirectional mood effects of GLP-1 receptor agonists, and its expression level needs to be maintained within a specific physiological window to ensure mood homeostasis. This invention assesses the risk of developing mood disorders after using GLP-1 receptor agonists by detecting the expression level or activity of TTR in subjects. This invention also provides kits for assessing the mood side effects of GLP-1 receptor agonists, methods for screening candidate drugs for the prevention or treatment of related mood disorders, and pharmaceutical compositions containing TTR or its agonists. This invention elucidates the molecular mechanism by which GLP-1 receptor agonists inhibit TTR expression through the cAMP / PKA / Gli3 signaling pathway, thereby affecting the ERK / CREB pathway and synaptic plasticity, providing novel targets and strategies for precise drug use, risk warning, and intervention for related mood disorders using GLP-1 receptor agonists.

Methods and compositions are provided for treating or preventing a neurological disease or disorder using an inhibitor of Glyoxalase 1 (GLO1). In some embodiments, the inhibitor is a small molecule. In certain embodiments, the disease or disorder is a sleep disorder, a mood disorder such as depression, epilepsy, an anxiety disorder, substance abuse, substance dependence or substance such as an alcohol withdrawal syndrome.

The invention discloses application of securinine in preparation of a medicine for relieving anxiety disorder of postmenopausal women. Female menopausal related mood disorder diseases are researched by constructing a bilateral ovariectomy mouse model, and mouse anxiety-like behaviors induced by ovariectomy can be quickly relieved within 30 minutes by single administration of a natural product securinine. The invention provides a medicine for treating postmenopausal female anxiety disorder, the medicine takes effect quickly, not only provides a brand new medicine candidate for quick intervention of menopausal related anxiety, but also defines a corresponding medication scheme, and has practical application potential.

The present disclosure discloses a composition of GLP-1 and PYY3-36 polypeptide analogues, a preparation method and use thereof, and relates to the technical field of biomedicines. The composition includes a GLP-1 polypeptide analogue and a PYY3-36 polypeptide analogue. Compared with the natural sequence of GLP-1 and the natural sequence of PYY3-36, the composition of the GLP-1 polypeptide analogue and the PYY3-36 polypeptide analogue has remarkable effects in ameliorating metabolic diseases such as obesity, diabetes mellitus, and fatty liver, and mood disorders such as anxiety and depression.

The present description relates to a method for treating a patient having a mood disorder, comprising administering to a subject in need a pharmaceutical composition comprising a base compound consisting substantially of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine or a pharmaceutically acceptable salt thereof in a specified dosage regimen.

Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I); and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

The present disclosure provides a crystalline form of enantiopure deuterium-enriched bupropion, pharmaceutical compositions, and methods of treating mood disorders, neurological disorders, movement disorders, cardiovascular disorders, metabolic disorders, and other disorders using a crystalline form of enantiopure deuterium-enriched bupropion.

The invention discloses a multi-mode mood disorder classification method based on fMRI and voice, and the method mainly aims at constructing an fMRI and voice interaction fusion network framework which is composed of three stages of network structures, namely, a double-branch feature extraction network used for carrying out the feature extraction of voice data and fMRI signals, and a multi-branch feature extraction network used for carrying out the feature extraction of the voice data and the fMRI signals. The feature interaction fusion network is used for converting the multi-modal features into fusion features containing key information of data of each modal, and the full connection layer network is used for mapping the fusion features to category probabilities. A brain network topological structure and voice features which are related to mood disorder classification tasks and have high discrimination capability are effectively extracted from fMRI and voice data; therefore, cross-modal causal association between the fMRI and the voice data is effectively mined, and high-precision and interpretable mood obstacle recognition and classification are realized.

The application discloses application of a Hepcidin modulator. Abnormal increase of Hepcidin in a ventral hippocampus region in a senescence process drives imbalance of iron homeostasis of neurons, and further induces an anxiety-like phenotype. Pharmacodynamic verification shows that administration of a Hepcidin inhibitor to cells of the ventral hippocampus can effectively reverse anxiety behavior of a senescence model animal. The pharmaceutical composition described in the application takes the Hepcidin pathway as an intervention target, and an active ingredient thereof is selected from the following: (1) a high-affinity Hepcidin inhibitor NOX-H94; and (2) a recombinant adeno-associated virus vector carrying a Hepcidin-targeted interference sequence, which is used for silencing expression of Hepcidin in neurons of the ventral hippocampus in vivo. The above-mentioned preparation provides a new molecular target and a drug candidate for clinical intervention of senescence-related emotional disorders.

The present disclosure relates to the field of medicine and discloses a novel human PYY3-36 analog. Compared with the naturally-occurring sequence of PYY3-36, the analog has a remarkable effect on ameliorating metabolic diseases such as obesity, diabetes and fatty liver, and on mood disorders such as anxiety and depression.

This invention belongs to the field of pharmaceutical formulation technology, specifically disclosing a gastrodin transdermal patch and its preparation method. The patch consists of a backing layer, a drug-containing matrix layer, and an anti-adhesive layer, using gastrodin as the active ingredient. It employs HP-β-CD inclusion technology, combined with an HPMC and PVP polymer backbone and an oleic acid-menthol composite transdermal enhancement system. The preparation utilizes solvent casting and low-temperature vacuum drying processes, which are mild and controllable. This invention effectively solves the problems of difficult transdermal absorption, easy recrystallization, and low bioavailability of gastrodin. The resulting patch has excellent adhesion, no skin irritation, high transdermal penetration, and good skin biocompatibility. It can efficiently cross the blood-brain barrier, regulate the neuroinflammatory microenvironment in the brain, significantly inhibit the colonization and progression of non-small cell lung cancer brain metastases, and strongly reverse tumor-related anxiety and depression-like mood disorders. It provides a novel drug delivery regimen with great clinical translational potential for the non-invasive synergistic treatment of brain tumors and their associated mood disorders.

The invention relates to particular substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and / or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use as agonists or antagonists of the serotonin (5-HT2A) receptor, preferably non-hallucinogenic biased agonists at the serotonin (5-HT2A) receptor, such as having agonism biased towards the beta-arrestin signaling pathway. Such compounds are useful for the treatment of mood disorders, general anxiety, social anxiety, depression, and other neuropsychiatric diseases.

Described herein, in part, are dosage forms and compositions useful for the prevention and / or treatment of diseases or conditions associated with aberrant T-type calcium channel function, such as epilepsy and epileptic syndromes (e.g., absent seizures, teenager myospastic epilepsy or genetic epilepsy), tremor (e.g., epilepsy seizures, spasmodic epilepsy, or hereditary epilepsy), or tremor (e.g., epilepsy seizures). Idiopathic tremor (e.g., idiopathic tremor) and psychiatric disorders (e.g., mood disorders (e.g., severe depressive disorder)). The invention also includes methods for modulating the function of T-type calcium channels.

The invention relates to particular substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and / or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use as selective agonists or antagonists serotonin (5-HT2A) receptor, preferably non-hallucinogenic biased agonists or antagonists at the serotonin (5-HT2A) receptor, such as having agonism biased towards the beta-arrestin signaling pathway, or as serotonin (5-HT2A) receptor antagonists. Such compounds are useful for the treatment of mood disorders, general anxiety, social anxiety, depression, anhedonia, and other neuropsychiatric diseases.

Described herein, in part, are dosage forms and compositions useful for preventing and / or treating a disease or condition relating to aberrant function of a T-type calcium channel, such as epilepsy and epilepsy syndromes (e.g., absence seizures, juvenile myoclonic epilepsy, or a genetic epilepsy), tremor (e.g., essential tremor), and psychiatric disorder (e.g., mood disorders (e.g., major depressive disorder)). The present invention further comprises methods for modulating the function of a T-type calcium channel.

The present disclosure relates to a crystalline salt selected from the group consisting of crystalline N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethyl-1-amine fumarate and crystalline N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethyl-1-amine hydrochloride, a process for their preparation and their use for the treatment of mood disorders. In addition, the present disclosure relates to polymorphs of the above salts. In addition, the present disclosure relates to an oily or amorphous N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethyl-1-amine, a process for its preparation and its use for the treatment of mood disorders.

The application discloses application of a liver 20-HETE synthesis inhibitor in preparation of a medicine for treating perimenstrual mood disorders. The application constructs a perimenstrual mouse model through ovariectomy, and it is observed through behavior test that the perimenstrual model mouse shows obvious depressive and anxious behaviors. The expression of 20-HETE synthesis enzyme Cyp4a12a in the liver of the ovariectomy model mouse is significantly increased, and the 20-HETE level in the plasma is significantly increased. Through intervention by using a liver 20-HETE synthesis enzyme inhibitor TS-011, the 20-HETE content in the plasma of the ovariectomy mouse is significantly reduced, and the depressive and anxious behaviors of the mouse are obviously improved. It is found by the application that the liver 20-HETE synthesis inhibitor can be applied to development or preparation of a perimenstrual mood disorder treatment medicine with low side effects and high clinical acceptance, and has high clinical transformation value.

The present disclosure provides ergoline compounds and their use in the treatment of mood disorders. Pharmaceutical compositions and methods of making various ergoline compounds are provided.

Novel tryptamine compounds according to Formulas (1), (2), (3), (4), (5), and (6) and sub-formulas thereof, pharmaceutical salts thereof, and pharmaceutical compositions thereof, and methods of treating mood disorders, including depressive disorders and bipolar disorders, comprising administering a therapeutically effective amount of a compound according to any one of Formulas (1), (2), (3), (4), (5), and (6) or a pharmaceutical composition thereof to a subject in need thereof.

This invention belongs to the field of pharmaceutical technology, specifically relating to the application of N-methyltyramine in the preparation of drugs for improving anger and irritability. The CAS number of the N-methyltyramine (NMT) is 370-98-9. Experimental results show that NMT can directly target and positively regulate the γ-aminobutyric acid type A receptor (GABA). a NMT activates the downstream AC5-cAMP-PKA signaling pathway, thereby improving abnormal emotional states such as anger and depression. Through network pharmacology, molecular docking, micro-thermophoresis experiments, animal behavioral experiments, and cell experiments, NMT significantly improves the behavior of model animals. Therefore, this invention reveals for the first time that NMT improves abnormal emotional states such as anger and depression through GABA. a The mechanism by which R-related signaling pathways play a role in mood regulation can be used to prepare drugs for treating mood disorders such as anxiety, depression, and post-traumatic stress disorder, and has good application prospects.

The application provides a depression disorder identification method and device based on facial behavior data, which enables a neural network model to identify whether a subject has a depression disorder through facial behavior data based on any content and form of stimulation data, improves the generalization performance of the neural network model, and has important significance for deploying the model in an actual medical scene. The method comprises the following steps: obtaining target stimulation data for stimulating the senses of a target subject; obtaining target facial behavior data generated by the target subject after being stimulated by the target stimulation data; encoding the target stimulation data to obtain a first vector representation; encoding the target facial behavior data to obtain a second vector representation; inputting the first vector representation and the second vector representation into a neural network model to obtain a classification result output by the model for indicating whether there is a depression disorder by identifying the relationship characteristics between the target stimulation data and the target facial behavior data.

The present invention provides a composition which comprises a compound which is a mixture of deuterium containing and non-deuterium containing molecules having the structure:wherein R1 iswherein at least one of H1, H2 or H3 is a deuterium-enriched —H site, orwherein at least one of H1, H2, H3, H4 or H5 is a deuterium-enriched —H site,or a pharmaceutically acceptable salt of the compound, and methods of using the composition to treat pain, depressive disorders, mood disorders, anxiety disorders, opioid use disorders, and opioid withdrawal symptoms.

The invention discloses application of enterobacter murine in preparation of a medicine for preventing or treating depression, and belongs to the field of medicine. The invention relates to an application of enterobacter murine in preparation of a medicine for preventing or treating depression. According to the present invention, the enterobacter muricatum is Muriaculum gardrongarter, and is preserved in the German Microbiological Culture Collection Center, and the preservation number is DSM 108194. The enterobacter muricatum can be used for preparing the enterobacter muricatum, the invention discloses application of active enterobacter murine, namely application of the active enterobacter murine in preparation of drugs for preventing or treating depression. The sucrose preference of the mouse is improved to a certain extent, the mood disorder is obviously reduced after the enterobacter murine is administered, and compared with fluoxetine, depression caused by chronic social contusion stress can be more quickly improved. The medicine is suitable for clinical popularization and use.

Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I): and pharmaceutically acceptable salts thereof, wherein - - - - -, R1, R2, R3a, R3b, R4a , R4b, R5, R6, and R7 are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.